Literature DB >> 12962843

Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality.

J M Moreno1, V Cuervas-Mons, E Rubio, F Pons, A Herreros de T, V S Turrión, I Millán.   

Abstract

INTRODUCTION: Although chronic renal dysfunction (CRD) is a common complication among patients undergoing liver transplantation (OLT) its prevalence, risk factors, and impact on outcome have not been well defined. We aimed to assess the incidence of CRD, its associated risk factors and its impact on outcome. PATIENTS AND METHODS: The cohort of 289 consecutive adult first liver transplant patients with posttransplant follow-up longer than 6 months received cyclosporine in 230 patients (153 oil-based and 81 microemulsion formulation), tacrolimus in 55. CRD was defined as serum creatinine levels greater than 1.3 mg/dL for more than 6 months.
RESULTS: After a mean follow-up of 67 months, 138 patients (47.8%) displayed CRD. The prevalence of CRD was 30.9%, 41.5%, and 38.9% at 1, 5, and 13 years after OLT, respectively. Twelve patients (4.1%) developed end-stage renal failure. Male gender, older recipient age, pretransplant renal dysfunction and hyperuricemia, posttransplant in-hospital renal dysfunction and hyperuricemia, and renal dysfunction during the first 6 months after OLT were each significantly associated with the development of CRD. Survival was significantly lower (63%) among liver transplant patients with CRD than those without this complication (71%, P=.024).
CONCLUSIONS: CRD is an important cause of morbidity after OLT, although end-stage renal disease is infrequent. Because early renal dysfunction is associated with the development of CRD, and decreased long-term patient survival, efforts should be made to avoid early renal dysfunction after liver transplantation.

Entities:  

Mesh:

Year:  2003        PMID: 12962843     DOI: 10.1016/s0041-1345(03)00642-0

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  15 in total

1.  Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.

Authors:  Martin-Walter Welker; Nina Weiler; Wolf Otto Bechstein; Eva Herrmann; Christoph Betz; Mark Schöffauer; Stefan Zeuzem; Christoph Sarrazin; Kerstin Amann; Oliver Jung
Journal:  J Nephrol       Date:  2018-06-26       Impact factor: 3.902

2.  Deletion of Calcineurin Promotes a Protumorigenic Fibroblast Phenotype.

Authors:  Allyson Lieberman; Richard Barrett; Jaewon Kim; Kathy L Zhang; Diana Avery; James Monslow; Hyunsoo Kim; Bang-Jin Kim; Ellen Puré; Sandra Ryeom
Journal:  Cancer Res       Date:  2019-06-12       Impact factor: 12.701

3.  Risk factors for chronic anemia in pediatric orthotopic liver transplantation: analysis of data from the SPLIT registry.

Authors:  R I Liem; R Anand; W Yin; E M Alonso
Journal:  Pediatr Transplant       Date:  2011-12-21

Review 4.  Pre-transplant kidney function predicts chronic kidney disease after liver transplant: meta-analysis of observational studies.

Authors:  Fabrizio Fabrizi; Vivek Dixit; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

5.  Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.

Authors:  Alina M Allen; W Ray Kim; Terry M Therneau; Joseph J Larson; Julie K Heimbach; Andrew D Rule
Journal:  J Hepatol       Date:  2014-04-05       Impact factor: 25.083

Review 6.  Antibody immunosuppressive therapy in solid-organ transplant: Part I.

Authors:  Nadim Mahmud; Dusko Klipa; Nasimul Ahsan
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

7.  Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy.

Authors:  Yaojen Chang; Lorenzo Gallon; Colleen Jay; Kirti Shetty; Bing Ho; Josh Levitsky; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Liver Transpl       Date:  2014-09       Impact factor: 5.799

Review 8.  Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

Authors:  John S Bomalaski; Mike A Clark
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

9.  Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis.

Authors:  Yuan Kong; Dongping Wang; Yushu Shang; Wenhua Liang; Xiaoting Ling; Zhiyong Guo; Xiaoshun He
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

10.  The benefit of sirolimus maintenance immunosuppression and rabbit antithymocyte globulin induction in liver transplant recipients that develop acute kidney injury in the early postoperative period.

Authors:  Benjamin T Duhart; Winston A Ally; Amy G Krauss; Joanna Q Hudson; James D Eason; Vinaya Rao; Jason M Vanatta
Journal:  J Transplant       Date:  2015-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.